The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor immune microenvironment of KRAS G12C mutated pancreatic cancer as compared to other mutations and non-cancer pancreata.
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; GlaxoSmithKline; Histosonics; Incyte; Ipsen; QED Therapeutics; Rafael Pharmaceuticals; SERVIER
Research Funding - Actuate Therapeutics (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
 
Valerie Gunchick
Consulting or Advisory Role - Cornerstone Pharmaceuticals
 
Simi Paul
No Relationships to Disclose
 
Thomas Enzler
Research Funding - Abbvie; Amgen; AstraZeneca; AstraZeneca; BioMed Valley Discoveries (Inst); CanBas; Exelixis; Exelixis; Five Prime Therapeutics; Hoosier Cancer Research Network; NeoImmuneTech; Taiho Oncology
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; BioMed Valley Discoveries; Seagen
 
Timothy Frankel
No Relationships to Disclose